Loestrin Ruling Signals Non-Cash Deals Won't Evade Actavis

Law360, New York (February 23, 2016, 10:44 PM EST) -- With its ruling Monday that Warner Chilcott’s noncash settlements with generics makers over its contraceptive Loestrin could face antitrust scrutiny, the First Circuit fell into line with other courts and brought some possible closure to the debate over whether a "payment" under the U.S. Supreme Court's Actavis decision must be cash, attorneys say.

The First Circuit opinion echoed a prior Third Circuit ruling in its finding that noncash "reverse" payments meant to delay the release of competing generics could be targeted as anti-competitive under the high...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.